TY - JOUR
T1 - Allogenic synovia-derived mesenchymal stem cells for treatment of equine tendinopathies and desmopathies — proof of concept
AU - Reis, Inês Leal
AU - Lopes, Bruna
AU - Sousa, Patrícia
AU - Sousa, Ana Catarina
AU - Branquinho, Mariana
AU - Caseiro, Ana Rita
AU - Pedrosa, Sílvia Santos
AU - Rêma, Alexandra
AU - Oliveira, Cláudia
AU - Porto, Beatriz
AU - Atayde, Luís
AU - Amorim, Irina
AU - Alvites, Rui
AU - Santos, Jorge Miguel
AU - Maurício, Ana Colette
N1 - Funding Information:
Mariana Vieira Branquinho (SFRH/BD/146172/2019), Ana Catarina Sousa (SFRH/BD/146689/2019), and Bruna Lopes (2021.05265.BD) acknowledge Fundaçāo para a Ciência e Tecnologia (FCT) for financial support. Rui Damásio Alvites acknowledges the Animal Science Studies Centre (CECA), Agroenvironment, Technologies and Sciences Institute (ICETA), Porto University (UP), and FCT for the funding and availability of all technical, structural, and human resources necessary for the development of this work. The author Patrícia Sousa acknowledges Instituto Politécnico de Leiria–Center for Rapid and Sustainable Product Development (CDRSP), University of Porto (UP), Centro de Estudos de Ciêcia Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) for the funding (UIDB/04044/2020) and availability of all resources needed for this work. The work was supported through the project UIDB/00211/2020 funded by FCT/MCTES national funds. This research was funded by Projects PEst-OE/AGR/UI0211/2011 from FCT, and COMPETE 2020, from ANI–Projetos ID&T Empresas em Copromoçāo, and by the project “Print-on-Organs–Engineering bioinks and processes for direct printing on organs” with the reference POCI-01-0247-FEDER-033877, by the project “Bone2Move- Development of “in vivo” experimental techniques and modeling methodologies for the evaluation of 4D scaffolds for bone defect in sheepmodel: an integrative research approach” with the reference POCI-01-0145-FEDER-031146.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/4/11
Y1 - 2023/4/11
N2 - Tendon and ligament injuries are frequent in sport horses and humans, and such injuries represent a significant therapeutic challenge. Tissue regeneration and function recovery are the paramount goals of tendon and ligament lesion management. Nowadays, several regenerative treatments are being developed, based on the use of stem cell and stem cell-based therapies. In the present study, the preparation of equine synovial membrane mesenchymal stem cells (eSM-MSCs) is described for clinical use, collection, transport, isolation, differentiation, characterization, and application. These cells are fibroblast-like and grow in clusters. They retain osteogenic, chondrogenic, and adipogenic differentiation potential. We present 16 clinical cases of tendonitis and desmitis, treated with allogenic eSM-MSCs and autologous serum, and we also include their evaluation, treatment, and follow-up. The concerns associated with the use of autologous serum as a vehicle are related to a reduced immunogenic response after the administration of this therapeutic combination, as well as the pro-regenerative effects from the growth factors and immunoglobulins that are part of its constitution. Most of the cases (14/16) healed in 30 days and presented good outcomes. Treatment of tendon and ligament lesions with a mixture of eSM-MSCs and autologous serum appears to be a promising clinical option for this category of lesions in equine patients.
AB - Tendon and ligament injuries are frequent in sport horses and humans, and such injuries represent a significant therapeutic challenge. Tissue regeneration and function recovery are the paramount goals of tendon and ligament lesion management. Nowadays, several regenerative treatments are being developed, based on the use of stem cell and stem cell-based therapies. In the present study, the preparation of equine synovial membrane mesenchymal stem cells (eSM-MSCs) is described for clinical use, collection, transport, isolation, differentiation, characterization, and application. These cells are fibroblast-like and grow in clusters. They retain osteogenic, chondrogenic, and adipogenic differentiation potential. We present 16 clinical cases of tendonitis and desmitis, treated with allogenic eSM-MSCs and autologous serum, and we also include their evaluation, treatment, and follow-up. The concerns associated with the use of autologous serum as a vehicle are related to a reduced immunogenic response after the administration of this therapeutic combination, as well as the pro-regenerative effects from the growth factors and immunoglobulins that are part of its constitution. Most of the cases (14/16) healed in 30 days and presented good outcomes. Treatment of tendon and ligament lesions with a mixture of eSM-MSCs and autologous serum appears to be a promising clinical option for this category of lesions in equine patients.
KW - Allogenic
KW - Cell-based therapies
KW - Clinical trials
KW - Ligament
KW - Mesenchymal stem cells
KW - Sport horses
KW - Synovial mesenchymal stem cell
KW - Tendon
UR - http://www.scopus.com/inward/record.url?scp=85153791162&partnerID=8YFLogxK
U2 - 10.3390/ani13081312
DO - 10.3390/ani13081312
M3 - Article
C2 - 37106875
AN - SCOPUS:85153791162
SN - 2076-2615
VL - 13
JO - Animals
JF - Animals
IS - 8
M1 - 1312
ER -